Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Condition: Acute Bacterial Conjunctivitis Interventions: Drug: IVIEW-1201; Drug: Ofloxacin Eye Drops Sponsor: IVIEW Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Condition: Allergic Conjunctivitis Interventions: Drug: rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo); Drug: Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution Sponsor: Bausch & Lomb Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Condition: Acute Bacterial Conjunctivitis Interventions: Drug: IVIEW-1201; Drug: Ofloxacin Eye Drops Sponsor: IVIEW Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Condition: Allergic Conjunctivitis Interventions: Drug: rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo); Drug: Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution Sponsor: Bausch & Lomb Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2023 Category: Research Source Type: clinical trials
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Condition: Seasonal Allergic Conjunctivitis Interventions: Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution; Drug: Ketotifen fumarate ophthalmic solution 0.035% (n = 56); Drug: Brimonidine tartrate ophthalmic solution 0.025% (n = 56); Drug: Experimental: Vehicle ophthalmic solution (n = 56) Sponsor: Bausch & Lomb Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2022 Category: Research Source Type: clinical trials